View summary of this

Transcription

1 In-Vitro Colorectal Cancer Screening Tests Market By Product (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Panel DNA Tests) Is Expected To Reach USD Million In 2022 The global market for in-vitro colorectal cancer screening tests is expected to reach USD million by 2022, according to a new study by Grand View Research, Inc. Increasing incidences of colorectal cancer and the development of novel CRC screening tests employing methods of genetic screening are some primary factors expected to drive market growth over the forecast period. The implementation of government regulations introducing compulsory application of cancer screening tests, introduction of minimally invasive tests which screen for CRC using DNA and genomic biomarkers, and the presence of high unmet needs are expected to fuel the growth of the in-vitro colorectal cancer screening tests market over the forecast period. Apart from the already present genetic tests for CRC screening in the market, this segment of the market is relatively new and still in its nascent stages. Many biomarker tests are still under investigational research and yet others in their development phase. The major market players have significant products related to colorectal cancer screening using biomarkers and DNA screening in their development and approval pipelines which are expected to be fully commercialized within the next seven years. The introduction of these novel genetic tests in the market is expected to enhance revenue generation in the market and positively influence penetration rates. View summary of this

2 Global In-vitro colorectal cancer screening tests market, by product, (USD Million) Table of Content Chapter 1 Methodology and Scope 1.1 Research Methodology 1.2 Research Scope & Assumptions 1.3 List of Data Sources Chapter 2 Executive Summary Chapter 3 In-Vitro Colorectal Cancer Screening Tests Industry Outlook 3.1 Market segmentation 3.2 Market size and growth prospects 3.3 In-Vitro Colorectal Cancer Screening Tests: Market dynamics Market driver analysis Growing incidence of colon and rectal cancers Growing accuracy of colorectal cancer screening by use of genetic testing Presence of a number of colorectal cancer screening products in pipeline Market restraint analysis Pending investigational evidence for certain genetic screening tests

3 Difficulty to undertake CRC screening tests to encompass the entire Lack of cancer screening guideless in Asia Pacific region 3.4 Industry Analysis - Porter s 3.5 Key opportunities prioritized 3.6 In-Vitro Colorectal Cancer Screening Tests market - PESTEL analysis Chapter 4 In-Vitro Colorectal Cancer Screening Tests Product Outlook 4.1 In-vitro colorectal cancer screening tests market share by test type, 2014 & Fecal Occult Blood Tests Fecal occult blood tests market, (USD Million) Guaiac FOB Stool Test Guaiac FOB stool tests market, (USD Million) Immuno-FOB agglutination test Immuno-FOB agglutination tests market, (USD Million) Lateral Flow Immuno-FOB Test Lateral flow Immuno-FOB tests market, (USD Million) Immuno-FOB ELISA test Immuno-FOB ELISA tests market, (USD Million) 4.3 Biomarker tests market Tumor M2-PK Stool Test Tumor M2-PK stool tests market, (USD Million) Transferrin assays Transferrin assays market, (USD Million) 4.4 CRC DNA screening tests CRC DNA screening tests market, , (USD Million) Methylated Gene Testing Methylated gene testing market, (USD Million) Panel DNA Tests Panel DNA tests market, (USD Million) Chapter 5 In-vitroColorectal Cancer Screening Tests Regional Outlook 5.1 In-vitro colorectal cancer screening tests market share by region, 2014 & North America North America market, by product, (USD Million) U.S. market, by product, (USD Million) Canada market, by product, (USD Million) 5.3 Europe Europe market, by product, (USD Million) Germany market, by product, (USD Million) UK market, by product, (USD Million) 5.4 Asia Pacific Asia Pacific market, by product, (USD Million) Japan market, by product, (USD Million) China market, by product, (USD Million) 5.5 Latin America

4 5.5.1 Latin America market, by product, (USD Million) Brazil market, by product, (USD Million) Mexico market, by product, (USD Million) 5.6 MEA MEA market, by product, (USD Million) South Africa market, by product, (USD Million) Chapter 6 Competitive Landscape 6.1 Abbott Molecular Inc Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.2 Alere Inc Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.3 Beckman Coulter Inc Company Overview Financial Performance Product Benchmarking 6.4 Eiken Chemical Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.5 Epigenomics AG Corporation Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.6 Sysmex Corporation Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.7 Siemens Healthcare Ltd Company Overview Financial Performance Product Benchmarking 6.8 Quest Diagnostics Incorporated Company Overview Financial Performance

5 6.8.3 Product Benchmarking Strategic Initiatives 6.9 CompanianDx Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.10 OncoCyte Corporation-Biotime Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.11 Merck Millipore Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.12 GeneNews Ltd Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.13 BioMarCare Technologies Ltd Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.14 Immunostics Inc Company Overview Financial Performance Product Benchmarking 6.15 Exiqon Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.16 Kyowa Medex Co. Ltd Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.17 Mode Diagnostics Company Overview

6 Financial Performance Product Benchmarking Strategic Initiatives 6.18 Randox Laboratories Ltd Company Overview Financial Performance Product Benchmarking Strategic Initiatives 6.19 R-Biopharm Incorporation Company Overview Financial Performance Product Benchmarking Strategic Initiatives Browse full List of Tables TABLE 1 In-Vitro Colorectal Cancer Screening Tests Market - Industry Summary & Key Buying Criteria TABLE 2 Global market, by test type, (USD Million) TABLE 3 Global market, by region, (USD Million) TABLE 4 In-Vitro Colorectal Cancer Screening Tests - Key market driver analysis TABLE 5 In-Vitro Colorectal Cancer Screening Tests - Key market restraint analysis TABLE 6 North America market by test type, (USD Million), TABLE 7 North America fecal occult blood tests market, (USD Million) TABLE 8 North America biomarker tests market, (USD Million) TABLE 9 North America CRA DNA screening tests market, (USD Million) TABLE 10 U.S. i market by test type, (USD Million) TABLE 11 U.S. fecal occult blood test market, (USD Million) TABLE 12 U.S biomarker test market, (USD Million) TABLE 13 U.S. CRC DNA screening test market, (USD Million) TABLE 14 Canada market by test type, (USD Million) TABLE 15 Canada fecal occult blood test market, (USD Million) TABLE 16 Canada CRC DNA screening test market, (USD Million) TABLE 17 Canada biomarker test market, (USD Million) TABLE 18 Europe market by test type, (USD Million) TABLE 19 Europe fecal occult blood test market, (USD Million) TABLE 20 Europe biomarker test market, (USD Million) TABLE 21 Europe CRC DNA screening test market, (USD Million)

7 TABLE 22 Germany market by test type, (USD Million) TABLE 23 Germany fecal occult blood tests market, (USD Million) TABLE 24 Germany biomarker tests market, (USD Million) TABLE 25 Germany CRC DNA screening test, (USD Million) TABLE 26 UK market by test type, (USD Million) TABLE 27 UK fecal occult blood tests market, (USD Million) TABLE 28 UK biomarker tests market, (USD Million) TABLE 29 UK CRC DNA screening tests market, (USD Million) TABLE 30 Asia Pacific market by test type, (USD Million) TABLE 31 Asia Pacific fecal occult blood tests, (USD Million) TABLE 32 Asia Pacific biomarker tests, (USD Million) TABLE 33 Asia Pacific CRC DNA screening tests, (USD Million) TABLE 34 Japan market by test type, (USD Million) TABLE 35 Japan fecal occult tests market (USD Million) TABLE 36 Japan biomarker tests market (USD Million) TABLE 37 Japan CRC DNA screening tests market (USD Million) TABLE 38 China market by test type, (USD Million) TABLE 39 China fecal occult blood tests market, (USD Million) TABLE 40 China biomarker tests market, (USD Million) TABLE 41 China CRC DNA screening tests market, (USD Million) TABLE 42 Latin America market by test type, (USD Million) TABLE 43 Latin America fecal occult blood tests market, (USD Million) TABLE 44 Latin America biomarker tests market, (USD Million) TABLE 45 Latin America CRC DNA screening tests market, (USD Million) TABLE 46 Brazil market by product, (USD Million) TABLE 47 Brazil fecal occult blood tests market, (USD Million) TABLE 48 Brazil biomarker tests market, (USD Million) TABLE 49 Brazil CRC DNA screening tests market, (USD Million) TABLE 50 Mexico market by test type, (USD Million) TABLE 51 Mexico fecal occult blood tests market, (USD Million) TABLE 52 Mexico biomarker tests market, (USD Million) TABLE 53 Mexico CRC DNA screening tests market, (USD Million) TABLE 54 MEA market by test type, (USD Million) TABLE 55 MEA fecal occult blood tests market, (USD Million) TABLE 56 MEA biomarker tests market, (USD Million) TABLE 57 MEA CRC DNA screening tests market, (USD Million) TABLE 58 South Africa by test types, (USD Million) TABLE 59 South Africa fecal occult blood tests market, (USD Million) TABLE 60 South Africa biomarker tests market, (USD Million) TABLE 61 South Africa CRC DNA screening tests market, (USD Million) For More Information visit

8 List of Figures FIG. 1 In-vitro colorectal cancer screening tests: Market segmentation FIG. 2 Global market, (USD Million), FIG. 3 In-Vitro Colorectal Cancer Screening Tests: Market dynamics FIG. 4 In-Vitro Colorectal Cancer Screening Tests market - Porter s Analysis FIG. 5 Key opportunities prioritized, 2014 FIG. 6 In-vitro colorectal cancer screening tests market - PESTEL analysis FIG. 7 In-vitro colorectal cancer screening tests market share by test type, 2014 & 2022 FIG. 8 Global fecal occult blood tests market, (USD Million) FIG. 9 Global guaiac FOB stool tests market, (USD Million) FIG. 10 Immuno-FOB agglutination tests market, (USD Million) FIG. 11 Lateral flow immuno-fob tests market, (USD Million) FIG. 12 Immuno-FOB ELISA tests market, (USD Million) FIG. 13 Global biomarker tests market, (USD Million) FIG. 14 Tumor M2-PK stool tests, (USD Million) FIG. 15 Transferrin assays market, (USD Million) FIG. 16 Global CRC DNA screening tests market, (USD Million) FIG. 17 Methylated gene testing market, (USD Million) FIG. 18 Panel DNA tests market, (USD Million) FIG. 19 In-vitro colorectal cancer screening tests market share by region, 2014 & 2022 FIG. 20 North America market, (USD Million) FIG. 21 U.S. in-vitro colorectal cancer screening tests, (USD Million) FIG. 22 Canada in-vitro colorectal cancer screening tests, (USD Million) FIG. 23 Europe in-vitro colorectal cancer screening tests, (USD Million) FIG. 24 Germany in-vitro colorectal cancer screening tests, (USD Million) FIG. 25 UK in-vitro colorectal cancer screening tests, (USD Million) FIG. 26 Asia Pacific in-vitro colorectal cancer screening tests, (USD Million) FIG. 27 Japan in-vitro colorectal cancer screening tests, (USD Million) FIG. 28 China in-vitro colorectal cancer screening tests, (USD Million) FIG. 29 Latin America In-vitro colorectal cancer screening tests, (USD Million) FIG. 30 Brazil in-vitro colorectal cancer screening tests, (USD Million) FIG. 31 Mexico In-vitro colorectal cancer screening tests, (USD Million) FIG. 32 MEA in-vitro colorectal cancer screening tests, (USD Million) FIG. 33 South Africa in-vitro colorectal cancer screening tests, (USD Million) Further key findings from the study suggest: The in-vitro colorectal cancer screening tests market was found to be dominated by fecal occult blood tests owing to their higher usage rates and easy applicability to large groups of population at once for cancer screening.

9 The more conventional guaiac FOB stool test, even though still occupy a significant share of the market, are expected to lose market share to their counterpart FOB tests which involve immunological testing along with the conventional testing. The investigation and development of newer more accurate methods for colorectal cancer screening have led to the development of biomarker and DNA screening tests. Tumor M2-PK Stool test is currently the most widely used screening test among biomarker and DNA screening tests and is expected to gain revenue share over the forecast period. North America accounted for the largest share of the in-vitro colorectal cancer screening tests market in 2014 owing to high incidences of colorectal cancer and presence of a large base of geriatric population in the region. Europe accounted for a significant market share in 2014 owing to the presence of high cancer prevalence levels in the region. Colorectal cancer is the second most common cancer in both men and women after lung and breast cancer. Commission of the European Communities has estimated that 500 million screening examinations are expected to be conducted for colorectal and cervical cancer in the publicly mandated programmes in EU from 2010 to Key participants of the in-vitro colorectal cancer screening tests market include Randox Laboratories, Sysmex, Immunostics, Beckman Coulter, Abbott Molecular, Epigenomics, Alere, Siemens Healthcare, Eiken Chemical, Kyowa Medex, Quest Diagnostics, Oncocyte, Companion Dx, Merck Millipore, ExiQon, Mode Diagnostics, and R- Biopharm. Request free sample of this For the purpose of this study, Grand View Research has segmented the in-vitro colorectal cancer screening tests market on the basis of product and region: Global In-Vitro Colorectal Screening Tests Market, Product Outlook (Revenue, USD Million, ) Fecal Occult Blood Tests Guaiac FOB Stool Test Immuno-FOB Agglutination Test Lateral Flow Immuno-FOB Test Immuno-FOB ELISA Test Biomarker Tests Tumor M2-PK Stool Test Transferrin Assays CRC DNA Screening Tests

10 Methylated Gene Testing Panel DNA Tests In-Vitro Colorectal Screening Tests Market, Regional Outlook (Revenue, USD Million, ) North America U.S. Canada Europe Germany UK Asia Pacific Japan China Latin America Brazil Mexico MEA South Africa Browse All Reports of this About Grand View Research Grand View Research, Inc. is a market research and consulting company that provides off-theshelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deepseated understanding of varied business environments, Grand View Research provides strategic objective insights.

11 Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: Toll Free: Website: Grand View Research Blog Site: